You are here

Scheduling delegate's final decisions, March 2016

Scheduling medicines and poisons

17 March 2016

Book pagination

2. Summary

Part A - Final decisions on matters referred to an expert advisory committee

2. Scheduling proposals referred to the November 2015 meeting of the Advisory Committee on Medicines Scheduling (ACMS#16)

Summary of delegate's final decisions
Substance Final decision
Bismuth oxychloride The delegate's final decision is that the current scheduling for bismuth oxychloride remains appropriate
Naproxen

APPENDIX H - New entry

Proposed implementation date: 1 June 2016

Paracetamol

The delegate has deferred making a final decision at this time regarding the scheduling of paracetamol when combined with ibuprofen. This is due to a late submission received during the most recent consultation period, and allows the submission to be given due consideration before the delegate makes a final decision. The final decision will be made before the end of April.

Piracetam The delegate's final decision is that the current scheduling of piracetam remains appropriate.
Lansoprazole, omeprazole and rabeprazole

The delegate's final decision is to include lansoprazole, omeprazole, rabeprazole in Schedule 2:

Lansoprazole

Schedule 2 - New entry

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

Schedule 3 - Amendment

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.

Schedule 4 - Amendment

LANSOPRAZOLE except when included in Schedule 2 or 3.

Omeprazole

Schedule 2 - New entry

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

Schedule 3 - Amendment

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.

Schedule 4 - Amend entry

OMEPRAZOLE except when included in Schedule 2 or 3.

Rabeprazole

Schedule 2 - New entry

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days' supply.

Schedule 3 - Amendment

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.

Schedule 4 - Amendment

RABEPRAZOLE except when included in Schedule 2 or 3.

Proposed implementation date: 1 June 2016

Flubromazolam

Schedule 9 - New entry

FLUBROMAZOLAM

Proposed implementation date: 1 June 2016

Thymosin Beta 4 (Thymosin β4)

Schedule 4 - New entries

THYMOSIN BETA 4 (THYMOSIN Β4)

TB-500

FIBROBLAST GROWTH FACTORS

Appendix D, Item 5 - New entries

THYMOSIN BETA 4 (THYMOSIN Β4)

TB-500

FIBROBLAST GROWTH FACTORS

Proposed implementation date: 1 June 2016

Book pagination